How can cholesterol efflux capacity be used as a risk factor for atherosclerotic cardiovascular disease?
Author:
- 14 October 2025
- journal article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 23 (11) , 647-653
Abstract
High-density lipoprotein cholesterol (HDL-C) has long been regarded as 'good cholesterol,' but clinical trials and epidemiological studies have demonstrated that simply raising HDL-C levels does not reduce cardiovascular events. Attention has therefore shifted from HDL-C quantity to HDL functionality. This review summarizes evidence from PubMed and Web of Science (2011-2024) on cholesterol efflux capacity (CEC), the most widely studied HDL functionality. CEC reflects the ability of HDL to remove cholesterol from macrophages, representing the first step of reverse cholesterol transport. Cohort and case-control studies consistently indicate that CEC provides incremental predictive value for atherosclerotic cardiovascular disease (ASCVD) beyond traditional lipid parameters. However, results vary across familial hypercholesterolemia cohorts, highlighting the influence of assay methods, treatment exposure, and HDL remodeling. The review also addresses lifestyle and genetic factors (e.g. alcohol consumption, ALDH2 polymorphisms), oxidative stress, and methodological challenges that complicate CEC measurement and standardization. While CEC is a promising surrogate marker, it remains a phenomenon rather than a therapeutic target, and there is no conclusive evidence that increasing CEC reduces ASCVD events. Future research should focus on disease-specific molecules, such as FABP5 and ORM1, that impair HDL function. Identifying these pathways may yield novel biomarkers and therapeutic targets, offering a more precise approach to residual cardiovascular risk beyond HDL-C levels.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (KAKENHI 24K11299, KAKENHI/21K08143)
This publication has 23 references indexed in Scilit:
- Obstructive sleep apnea syndrome attenuated high-density lipoprotein functionJournal of Clinical Lipidology, 2024
- HDL, cholesterol efflux, and ABCA1: Free from good and evil dualismJournal of Pharmacological Sciences, 2022
- Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH–JAPAN studyJournal of Clinical Lipidology, 2018
- Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studiesEuropean Heart Journal, 2017
- Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophagesScientific Reports, 2017
- High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular ConditionsJACC, 2016
- Dysfunctional HDL and atherosclerotic cardiovascular diseaseNature Reviews Cardiology, 2015
- Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control studyThe Lancet Diabetes & Endocrinology, 2015
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular EventsNew England Journal of Medicine, 2014
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011